Application of compound 1125-0440 in preparation of BTLA inhibitor and lung cancer treatment medicine
Compound 1125-0440 addresses the problem of lung cancer cells escaping immune surveillance by binding to BTLA and inhibiting its transcription and expression, thus achieving effective treatment for NSCLC.
Patent Information
- Application Number
- CN202411181958.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-27
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-27
AI Technical Summary
Existing technologies are unable to effectively inhibit BTLA activity, leading to lung cancer cells escaping immune surveillance, promoting lung cancer growth and metastasis, and affecting the treatment efficacy of NSCLC.
Compound 1125-0440 was developed to inhibit the transcription and expression of BTLA by binding to it, thereby inhibiting the migration of lung cancer cells.
Compound 1125-0440 significantly reduced the transcription and protein expression of BTLA and inhibited the migration of lung cancer cells, providing a new therapeutic agent for NSCLC.
Smart Images

Figure CN118924719A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine and relates to the application of compound 1125-0440 in the preparation of BTLA inhibitors and lung cancer therapeutic drugs. Background Art
[0002] Lung cancer brings a heavy disease burden to the world and causes a large number of deaths. Non-small cell lung cancer (NSCLC) is one of the main types of lung cancer, accounting for 80%-85% of lung cancer cases.
[0003] The immune system is the body's natural defense system, responsible for identifying and clearing pathogens and abnormal cells to prevent the progression of disease. B and T lymphocyte attenuator (BTLA) is a member of the immunosuppressive receptor family and plays an important role in tumor immunity. BTLA inhibits T cell responses by binding to herpes virus entry mediator (HVEM), and blocking BTLA activates T cells. This mechanism can help tumor cells escape immune surveillance in the tumor microenvironment, thereby promoting tumor growth and metastasis. BTLA expression in NSCLC affects the function of T cells, thereby affecting the immune escape of tumors.
[0004] With the deepening of research on immune checkpoint inhibitors, BTLA has also become one of the potential therapeutic targets. In some studies, BTLA is believed to affect the effect of immunotherapy together with other immune checkpoint molecules. Therefore, finding new BTLA inhibitors is crucial for the treatment of NSCLC. Summary of the invention
[0005] The present invention finds that compound 1125-0440 can combine with BTLA to inhibit its activity, compound 1125-0440 can inhibit the transcription and expression of BTLA, and compound 1125-0440 can inhibit the migration of lung cancer cells.
[0006] The purpose of the present invention is to provide the application of compound 1125-0440, that is, to provide the application of compound 1125-0440 in the preparation of BTLA inhibitors and lung cancer therapeutic drugs.
[0007] The purpose of the present invention is achieved through the following technical solutions:
[0008] Use of compound 1125-0440 or a pharmaceutically acceptable salt thereof in the preparation of a BTLA inhibitor.
[0009] The structure of the compound 1125-0440 is shown below:
[0010]
[0011] Use of compound 1125-0440 or a pharmaceutically acceptable salt thereof in the preparation of an anti-tumor drug. The tumor is a tumor associated with high expression of BTLA.
[0012] Use of compound 1125-0440 or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating lung cancer. The lung cancer is non-small cell lung cancer (NSCLC). Further, the drug for treating lung cancer is a drug for inhibiting the migration of lung cancer cells.
[0013] The present invention has the following advantages and beneficial effects: The present invention discovers the new medicinal value of compound 1125-0440 and provides a new preventive and therapeutic drug for NSCLC or other BTLA-highly expressed tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 The effect of compound 1125-0440 on the proliferation of Hela and RAW 264.7 cells.
[0015] Figure 2 This is the result of the effect of compound 1125-0440 on the transcription level of BTLA.
[0016] Figure 3 This is the result of the effect of compound 1125-0440 on BTLA protein levels.
[0017] Figure 4 It is a diagram of the molecular docking of compound 1125-0440 and BTLA protein, A: docking conformation of BTLA and 1125-0440; B: highest affinity conformation of 1125-0440 and BTLA; C: diagram of the interaction between 1125-0440 and BTLA.
[0018] Figure 5 This is the SPR binding diagram of compound 1125-0440 and BTLA protein.
[0019] Figure 6 The compound 1125-0440 inhibits the migration of lung cancer cell line A549. A: The migration effect of 1125-0440 on A549; B: Mobility quantitative bar graph. DETAILED DESCRIPTION
[0020] The following examples are used to further illustrate the present invention, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art.
[0021] The compound 1125-0440 used in the following implementation was purchased from Taoshu Biotechnology; the statistical analysis of the results of the examples was performed using a two-tailed unpaired t-test, *: P<0.05, **: P<0.01, ***: P<0.001, ****: P<0.0001.
[0022] Example 1
[0023] Hela cells and RAW 264.7 cells were cultured and plated in 96-well cell culture plates. After the cells covered the bottom of the plate, different concentrations of compound 1125-0440 were added to the 96-well plate, and cells with only PBS were used as negative controls. After culturing in a 37°C CO2 incubator for 2 hours, the cells were washed 3 times with PBS, and then fresh culture medium containing 10% CCK8 solution was added to continue culturing for 3 hours, and the absorbance at OD590 was read using a spectrophotometer.
[0024] The calculation formula is: cell survival rate = [(absorbance of experimental well - absorbance of blank well) / (absorbance of control well - absorbance of blank well)] × 100%.
[0025] The results are as follows Figure 1 As shown, the addition of different concentrations of compound 1125-0440 had no effect on the proliferation of Hela cells and RAW 264.7 cells.
[0026] Example 2
[0027] Construction of shRNA recombinant plasmid: Dissolve DNA oligo in TE (pH=8.0) to a concentration of 100 μmol / L. Take the corresponding sense chain and antisense chain oligo (sequences as shown in Table 1) solutions for annealing. Annealing conditions: 95℃5min, 85℃5min, 75℃5min, 70℃5min, and store at 4℃. The shRNA template obtained after annealing is diluted to a final concentration of 200nmol / L for ligation reaction.
[0028] First, the pcDNA3.1(+) vector was double-digested with BamHI and KpnI. Then, the shDNA template was added and ligated with ligase to construct the recombinant plasmid. The recombinant plasmid was transformed into E. coli DH5α competent cells, and the transformed E. coli DH5α was spread on LB agar plates containing ampicillin. After culturing at 37°C for 16 hours, a single clone colony was picked and shaken overnight in LB medium containing ampicillin. After extracting the plasmid, it was identified by sequencing.
[0029] Table 1 BTLA-shRNA primer sequences
[0030]
[0031] Note: "" indicates restriction site.
[0032] Construction of BTLA silencing cell line (sh-BTLA): Non-small cell lung cancer cells A549 in good condition in the logarithmic growth phase were uniformly inoculated in a 6-well plate for culture. After the cell adhesion density reached about 60-80%, the old culture medium was aspirated and washed 2-3 times with sterile PBS to remove cell metabolites and cells in poor condition, and then 1.75mL / well of serum-free culture medium was added. First, the transfection reagent was prepared according to the instructions of Thermo Fisher Lipofectamine 3000, 125μL serum-free culture medium and 3.75μL Lipo3000 were gently mixed, 2.5μg of the above shRNA recombinant plasmid and 125μL serum-free culture medium and 5μL P3000 were gently mixed, and then the two were gently mixed, incubated at room temperature for 5 minutes, and then added to the 6-well plate. After 6 hours of culture, the culture medium in the 6-well plate was discarded, washed 1-2 times with sterile PBS, and then new complete culture medium was added. After 24 hours of culture, the green fluorescence was observed under a microscope to determine whether the transfection was successful.
[0033] sh-BTLA cells cultured overnight and A549 cells (5×10 5 The culture medium was washed off with PBS, and total RNA of the cell line was extracted using TRIzol reagent (Invitrogen), RNA reverse transcription was performed, and cDNA was prepared using the First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). Next, gene expression analysis was measured using SYBR Select Master Mix primers and the Bio-Rad Real-Time PCR System. mRNA expression was normalized to β-actin using the formula (ΔCt = Ct target gene - Ct internal reference) and expressed as relative mRNA expression (ΔΔCt = 2 -(ΔCt样品-ΔCt对照) ). Each expression analysis was performed at least three independent biological replicates. All experimental steps were performed according to the manufacturer's instructions (Thermo Fisher Scientific). The primer sequences are as follows:
[0034] BTLA Forward Primer: 5'-CATCTTAGCAGGAGATCCCTTTG-3',
[0035] BTLA Reverse Primer: 5'-GACCCATTGTCATTAGGAAGCA-3';
[0036] GAPDH Forward Primer: 5'-GCACCGTCAAGGCTGAGAAC-3',
[0037] GAPDH Reverse Primer: 5'-TGGTGAAGACCGCCAGTGGA-3'.
[0038] Results are visible Figure 2 , as the concentration of compound 1125-0440 increased, the transcription level of BTLA decreased significantly.
[0039] Example 3
[0040] A549 cells (5×10 5 ) were treated with 0, 1, 5, 10 and 15 μM compound 1125-0440 for 12 h, the culture medium was washed with PBS, and the cells were dissolved in RIPA buffer (MACKLIN) containing protease phosphatase inhibitors. The total protein concentration of each sample was measured and quantified using a BCA protein quantification kit (Beyotime). 15 μg of total protein in each sample was separated on a 10% SDS-polyacrylamide electrophoresis gel and electroblotted onto a polyvinylidene fluoride membrane (Millipore). The protein was incubated overnight with a primary antibody diluted 1:1000 or 1:2000, washed, and incubated with a goat anti-rabbit HRP antibody (1:5000, Beyotime) for two hours, and then developed using a Bio-Rad integrated gel imaging system. Anti-BTLA antibody (ab181406) was purchased from Abcam, and Anti-β-tubulin antibody (66240-1-Ig) was purchased from Proteintech.
[0041] The results are as follows Figure 3 As shown, with the increase of the concentration of compound 1125-0440, the expression level of BTLA protein decreased significantly, indicating that 1125-0440 has a direct inhibitory effect on BTLA protein.
[0042] Example 4
[0043] AUTODOCK4.2 was used to analyze the molecular docking mode of BTLA and compound 1125-0440. The BTLA structure ID is 2AW2, which is a BTLA-HVEM complex obtained from the RCSB database, and the HVEM protein was removed in the software MOE (v.2019.0102). The 2D and 3D structures of 1125-0440 were drawn by ChemBioDraw Ultra 14.0 and ChemBio3DUltra14.0, respectively. BTLA and 1125-0440 were pretreated, including hydrogenation, dehydration, protonation, and energy minimization. Through computational simulation methods, the predicted docking conformations and highest affinity conformations of BTLA and 1125-0440 are as follows Figure 4 A and 4B. The docking score of BTLA and 1125-0440 is -9.1082, which is judged to be a strong binding force. The interaction was completed using the PLIP online service (https: / / plip-tool.biotec.tu-dresden.de / plip-web / plip / index). The interaction between 1125-0440 and BTLA is shown in Figure 4 As shown in C.
[0044] Example 5
[0045] The equilibrium dissociation constants of BTLA and compound 1125-0440 were determined by surface plasmon resonance (LSPR) technology, further proving the interaction between BTLA protein and 1125-0440. BTLA protein was immobilized on a COOH sensor chip (Nicoya, Canada). The chip was rinsed with PBS (pH 7.4) to obtain a stable detection baseline. Increasing concentrations of 1125-0440 (0.09375 μM, 0.375 μM, 0.75 μM, 1.5 μM, 3 μM, 12 μM) were injected into the chip. PBS was set as a negative control. The speed of each cycle was set to 20 μL / min. The data obtained from the measurement were analyzed using Trace Drawer software. The interaction between BTLA and 1125-0440 was evaluated using the binding reaction kinetic parameters. Figure 5 As shown in Figure 2, the equilibrium dissociation constant (Kd) of BTLA and 1125-0440 calculated by Trace Drawer software is 3.25×10 -6 M, further indicating that BTLA has a strong binding affinity with 1125-0440.
[0046] Example 6
[0047] Cell migration: (1) Cell plating: Draw five even horizontal lines on the back of a six-well plate with a marker pen, add A549 cells or sh-BTLA cell suspension that has been pipetted and mixed into the wells, with approximately 7×10 cells per well. 5 The plate was shaken in a figure-8 manner to evenly cover the cells and incubated in a 37°C carbon dioxide incubator overnight.
[0048] (2) Scratching: The next day, use a 200 μL medium tip to scratch against a sterilized ruler. Keep the tip vertical and scratch quickly and continuously. Try to use the same tip to scratch each well. Slowly add 1 mL of PBS per well, gently shake the plate, wash the cells twice, wash away the detached cells, add serum-free medium, add 20 μM 1125-0440 to the 1125-0440 treatment group, and continue incubating in a 37°C incubator.
[0049] (3) Observation and photography: Samples were taken at 0 h and 24 h, and the migration of cells was observed under a microscope and photographed.
[0050] (4) Result analysis: Image J software was used to measure the pixels of the scratch area and calculate the distance between cells to compare the migration speed of cells. Migration rate = (distance between cells at the beginning - distance between cells after migration) / distance between cells at the beginning × 100%.
[0051] The results are visible Figure 6 The migration rate of the BTLA-silenced cell line was significantly reduced compared with the control group, and the inhibition of cell migration in the 1125-0440-added group was more obvious.
[0052] The above embodiments are only used to help illustrate the present invention. The implementation methods of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. Use of compound 1125-0440 or a pharmaceutically acceptable salt thereof in the preparation of a BTLA inhibitor, characterized in that: The structure of the compound 1125-0440 is shown below:
2. Use of compound 1125-0440 or a pharmaceutically acceptable salt thereof in the preparation of an anti-tumor drug, characterized in that:
3. The use according to claim 2, characterized in that: The tumor is a tumor associated with high expression of BTLA.
4. Use of compound 1125-0440 or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating lung cancer, characterized in that:
5. The use according to claim 4, characterized in that: The lung cancer is non-small cell lung cancer.
6. The use according to claim 4, characterized in that: The lung cancer therapeutic drug is a drug that inhibits the migration of lung cancer cells.
Citation Information
Patent Citations
Dyed and / or printed non-woven fabric
CN1535342A
2, 5-bis (p-aminophenyl) furan azo derivatives
US2852503A
Process for dyeing human hair with diazo salts
US4162893A
